Cross-modality validation of quantitative <SUP>90</SUP>Y imaging using a custom hepatopulmonary shunt phantom and patient data

YEYİN, NAMİ; ABUQBEITAH, Mohammad; DEMİR, MUSTAFA; Akyol, Sinem; TUNÇMAN KAYAOKAY, DUYGU; KESMEZACAR, FAHRETTİN; GÜNAY, Osman; ALMisned, Ghada; Issa, Bashar; Tekin, H.

doi:10.1007/s00411-026-01236-5

Cross-modality validation of quantitative <SUP>90</SUP>Y imaging using a custom hepatopulmonary shunt phantom and patient data

YEYİN N., ABUQBEITAH M., DEMİR M., Akyol S., TUNÇMAN KAYAOKAY D., KESMEZACAR F. F., ...Daha Fazla

RADIATION AND ENVIRONMENTAL BIOPHYSICS, cilt.65, sa.3, ss.887-895, 2026 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 65 Sayı: 3
Basım Tarihi: 2026
Doi Numarası: 10.1007/s00411-026-01236-5
Dergi Adı: RADIATION AND ENVIRONMENTAL BIOPHYSICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Compendex, EMBASE, Environment Index, INSPEC, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
Sayfa Sayıları: ss.887-895
Anahtar Kelimeler: 90Y microsphere therapy, 90Y PET/CT dosimetry, 90Y PET/MR dosimetry, 90Y SPECT/CT dosimetry
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

In this study the discrepancies in dose estimations from a Y-90-filled hepatopulmonary shunt phantom (HPSP) were analyzed using SPECT/CT, PET/CT, and PET/MR modalities. The dose variability was also evaluated among randomly selected individuals undergoing Y-90-microsphere therapy. The HPSP comprised a right lung of 1,101 cm & sup3;, a left lung of 863 cm & sup3;, a healthy liver parenchyma of 690 cm & sup3;, and two intrahepatic tumours of 202 cm & sup3; and 9.5 cm & sup3;. Y-90-chloride activity was diluted in water and injected into the phantom. SPECT/CT, PET/CT, and PET/MR were acquired with the phantom immersed in water. Absorbed dose was calculated for phantom compartments and for patients with liver tumours who were treated with Y-90-glass microspheres. The calculated lung shunt fraction (LSF) (12.0%) from the PET/MR images was closest to the actual LSF (11.03%), followed by PET/CT with 12.2% and SPECT/CT with 13.4% LSF. The deviation between the actual dose estimates and Y-90-PET/MR was - 0.1% for the large tumour (202 cm & sup3;), -10.5% for the small tumour (9.5 cm & sup3;), -7.5% for the healthy liver parenchyma, and 6.1% for the lung. For Y-90-PET/CT, the deviation was 4.8% for the large tumour, -7.5% for the small tumour, -15.5% for the healthy liver parenchyma, and 7.6% for the lung. In contrast, a significant disparity was observed in the Y-90-SPECT/CT modality, with deviations of -6.3% for the large tumour, -65.3% for the small tumour, -10.7% for the healthy liver parenchyma, and 18.2% for the lung. In the patient study, the doses from Tc-99m-MAA SPECT/CT and Y-90-PET/MR images were comparable, whereas Y-90-SPECT/CT yielded significantly lower dose estimates. The findings obtained demonstrate that Y-90-SPECT/CT generates significant inaccuracies in absorbed dose estimates mainly for small tumours. All modalities overestimated LSF and lung dose by less than 10% except SPECT/CT (18%). It is concluded that implementing an optimal imaging technique with robust scatter correction would mitigate the dose underestimate. Y-90-PET/CT and Y-90-PET/MR are the preferred methods for reliable dosimetry and precise dose-response assessment, especially owing to their robust correlation with Tc-99m-MAA SPECT/CT simulation.